Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.85

-4.5%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	2/20/2004 2:38:00 PM
From: jayhawk969	Read Replies (3) of 52153

Estora Approval I would appreciate a second and 3rd opinion. In listening to the Jan 22, webcast one more time, the following is what I hear: The PDUFA extension was for additional (or differently formatted data) regarding the carcinogenicity of Estora. Sepracor finds no data that is negative. This is a precaution and hopefully not a Bismark. If any of you go to ir.thomsonfn.com and select slide 23 --- below (at least it is this in windows Media Player); you can go to the section that directly reports this info from Dr Mark Corrigan. I appreciate any feedback. This is my single biggest concern regarding this filing.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next